These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32476539)

  • 21. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure.
    Chen CY; Stevenson LW; Stewart GC; Bhatt DL; Desai M; Seeger JD; Williams L; Jalbert JJ; Setoguchi S
    BMJ; 2015 Jul; 351():h3529. PubMed ID: 26174233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator.
    Martens P; Verbrugge FH; Nijst P; Dupont M; Nuyens D; Herendael HV; Rivero-Ayerza M; Tang WH; Mullens W
    Heart; 2017 Dec; 103(24):1977-1984. PubMed ID: 28716973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decision-making regarding primary prevention implantable cardioverter-defibrillators among older adults.
    Hess PL; Matlock DD; Al-Khatib SM
    Clin Cardiol; 2020 Feb; 43(2):187-195. PubMed ID: 31867773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study.
    Ruwald AC; Gislason GH; Vinther M; Johansen JB; Nielsen JC; Philbert BT; Torp-Pedersen C; Riahi S; Jøns C
    Europace; 2018 Sep; 20(FI2):f217-f224. PubMed ID: 29684191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).
    Cheng A; Zhang Y; Blasco-Colmenares E; Dalal D; Butcher B; Norgard S; Eldadah Z; Ellenbogen KA; Dickfeld T; Spragg DD; Marine JE; Guallar E; Tomaselli GF
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1084-91. PubMed ID: 25273351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of chronic total coronary occlusion on long-term outcomes in implantable cardioverter-defibrillator recipients with ischaemic heart disease.
    Nishikawa T; Fujino M; Nakajima I; Asaumi Y; Kataoka Y; Anzai T; Kusano K; Noguchi T; Goto Y; Nishimura K; Miyamoto Y; Kiso K; Yasuda S
    Europace; 2017 Jul; 19(7):1153-1162. PubMed ID: 27738062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of baseline heart failure burden on post-implantable cardioverter-defibrillator mortality among medicare beneficiaries.
    Chen CY; Stevenson LW; Stewart GC; Seeger JD; Williams L; Jalbert JJ; Setoguchi S
    J Am Coll Cardiol; 2013 May; 61(21):2142-50. PubMed ID: 23541973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Barriers to patients eligible for screening investigations and insertion of primary prevention implantable cardioverter defibrillators.
    Sadarmin PP; Wong KC; Rajappan K; Bashir Y; Betts TR
    Europace; 2014 Nov; 16(11):1575-9. PubMed ID: 24668515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Outcomes of Single- versus Dual-Chamber Implantable Cardioverter Defibrillators: Lessons from the Israeli ICD Registry.
    Konstantino Y; Haim M; Boxer J; Goldenberg I; Feldman A; Michowitz Y; Glikson M; Suleiman M;
    J Cardiovasc Electrophysiol; 2016 Jun; 27(6):718-23. PubMed ID: 26852908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chagas disease is associated with a worse prognosis at 1-year follow-up after implantable cardioverter-defibrillator for secondary prevention in heart failure patients.
    Vieira de Melo RM; de Azevedo DFC; Lira YM; Cardoso de Oliveira NF; Passos LCS
    J Cardiovasc Electrophysiol; 2019 Nov; 30(11):2448-2452. PubMed ID: 31502385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utilization and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Hypertrophic Cardiomyopathy.
    Goldstein SA; Kennedy KF; Friedman DJ; Al-Khatib SM; Wang A
    J Am Heart Assoc; 2023 Aug; 12(16):e029293. PubMed ID: 37586066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.
    Chan PS; Nallamothu BK; Spertus JA; Masoudi FA; Bartone C; Kereiakes DJ; Chow T
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):16-24. PubMed ID: 20031808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes?
    Ambrosy AP; Parzynski CS; Friedman DJ; Fudim M; Hernandez AF; Fonarow GC; Masoudi FA; Al-Khatib SM
    Circulation; 2018 Dec; 138(24):2787-2797. PubMed ID: 30565983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Occurrence of Implantable Cardioverter Defibrillator Therapies After Generator Replacement in Patients Who No Longer Meet Primary Prevention Indications.
    Kawata H; Hirai T; Doukas D; Hirai R; Steinbrunner J; Wilson J; Noda T; Hsu J; Krummen D; Feld G; Wilber D; Santucci P; Birgersdotter-Green U
    J Cardiovasc Electrophysiol; 2016 Jun; 27(6):724-9. PubMed ID: 26915696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced long-term overall mortality in heart failure patients with prolonged QRS treated with CRT combined with ICD vs. heart failure patients with narrow QRS treated with ICD only.
    Palmisano P; Accogli M; Pisanò EC; Zaccaria M; De Blasi S; Ponzetta MA; Valsecchi S; Milanese G; Lauretti M; Magliari F
    Europace; 2016 Sep; 18(9):1374-82. PubMed ID: 26612878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum amine-based metabolites and their association with outcomes in primary prevention implantable cardioverter-defibrillator patients.
    Zhang Y; Blasco-Colmenares E; Harms AC; London B; Halder I; Singh M; Dudley SC; Gutmann R; Guallar E; Hankemeier T; Tomaselli GF; Cheng A
    Europace; 2016 Sep; 18(9):1383-90. PubMed ID: 26498162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application and comparison of the FADES, MADIT, and SHFM-D risk models for risk stratification of prophylactic implantable cardioverter-defibrillator treatment.
    van der Heijden AC; van Rees JB; Levy WC; van der Bom JG; Cannegieter SC; de Bie MK; van Erven L; Schalij MJ; Borleffs CJ
    Europace; 2017 Jan; 19(1):72-80. PubMed ID: 28130376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of 2014 NICE defibrillator implantation guidelines in heart failure risk stratification.
    Cubbon RM; Witte KK; Kearney LC; Gierula J; Byrom R; Paton M; Sengupta A; Patel PA; Mn Walker A; Cairns DA; Rajwani A; Hall AS; Sapsford RJ; Kearney MT
    Heart; 2016 May; 102(10):735-40. PubMed ID: 26857212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.